Viridian Therapeutics, Inc. (VRDN)

Market Cap	776.08M
Revenue (ttm)	288,000
Net Income (ttm)	-218.13M
Shares Out	63.82M
EPS (ttm)	-4.49
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	508,681
Open	13.04
Previous Close	13.21
Day's Range	12.14 - 13.05
52-Week Range	10.93 - 24.84
Beta	1.06
Analysts	Buy
Price Target	31.56 (+159.54%)
Earnings Date	Aug 6, 2024

About VRDN

Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune dise...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 94
• Stock Exchange: NASDAQ
• Ticker Symbol: VRDN

Financial Performance

In 2023, VRDN's revenue was $314,000, a decrease of -82.28% compared to the previous year's $1.77 million. Losses were -$237.73 million, 83.0% more than in 2022.

Analyst Forecast

According to 11 analysts, the average rating for VRDN stock is "Buy." The 12-month stock price forecast is $31.56, which is an increase of 159.54% from the latest price.

Price Target

$31.56

(159.54% upside)

Analyst Consensus: Buy